Agios Pharmaceuticals Inc (AGIO) is Trading Higher on Unusual Volume for January 18

Equities Staff |

Agios Pharmaceuticals Inc (AGIO) experienced unusually high volume on Jan. 18, as the stock gained 3.27% to a closing price of $50.35. The stock saw 2.67 million shares trade hands over the course of the day on 13,221 trades. Given that the stock’s average daily volume over the last month has been 772,464 shares a day, this represents a pretty substantial spike over the norm.

Agios Pharmaceuticals Inc has a P/B ratio of 5.05. The stock has traded between $133.80 and $43.54 over the last 52-weeks, its 50-day SMA is now $60.37, and its 200-day SMA $88.38.

Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.

Headquartered in Cambridge, MA, Agios Pharmaceuticals Inc has 96 employees and is currently under the leadership of CEO David P. Schenkein.

For a complete fundamental analysis analysis of Agios Pharmaceuticals Inc, check out’s Stock Valuation Analysis report for AGIO. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth


Cruz Cobalt Corp is a cobalt mining company. It is engaged in the acquisition and exploration of mineral properties. Its projects include the Hector Cobalt prospect, the Bucke Cobalt prospect,…

Private Markets


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…